1 Day
Source:
المقر
Al-Hikma Reports Strong H1 Performance
Hikma Pharmaceuticals achieved a 4% increase in its revenues during the first half of 2026, reaching $1.728 billion. The branded medicines segment grew by 15%, maintaining its leading position in the Middle East and North Africa markets. The company continued to launch new products, registering 48 filings and launching 43 products in the first half of the year, while signing strategic partnerships, especially across the Middle East and North Africa region. Additionally, Hikma strengthened its presence in international markets, ranking seventh in the United States and third in Europe in the generic pharmaceuticals sector. The company projects revenue growth between 2% and 4% for 2026, reaffirming its commitment to long-term growth through investments in research and development and the expansion of its product portfolio.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)